Anavex Life Sciences (AVXL) 0.2000 $AVXL
Inflammatory Pain Therapeutics Pipeline Review 2014 - 36 Companies and 67 Drug Profiles
M2 - Thu Sep 11, 4:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v44nlf/inflammatory_pain) has announced the addition of the "Inflammatory Pain - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Inflammatory Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammatory Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Takeda Pharmaceutical Company Limited - Glenmark Pharmaceuticals Ltd. - Pfizer Inc. - Evotec AG - Anavex Life Sciences Corp. - Array BioPharma Inc. - Pluristem Therapeutics Inc. - BCN Peptides, S.A. - Upsher-Smith Laboratories, Inc. - Grunenthal GmbH - Integral Molecular, Inc. - AngioChem Inc. - Asahi Kasei Pharma Corp. - Hydra Biosciences, Inc. - NeurAxon, Inc. - Cara Therapeutics, Inc. - CLL Pharma - Dompe Farmaceutici S.p.A. - Lohocla Research Corporation - MAKScientific, LLC - RaQualia Pharma Inc. - Sunovion Pharmaceuticals Inc. - Adynxx, Inc. - Kareus Therapeutics, SA - AnaBios Corporation - Creabilis SA - Istituto Italiano di Tecnologia - Infirst Healthcare Limited - AbbVie Inc. - Epirus Biopharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/v4...atory_pain
Anavex Supports Alzheimer's Foundation of America's 3rd Annual Concepts in Care Educational Conference
GlobeNewswire - Mon Sep 08, 6:36AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, today announced its corporate sponsorship of the upcoming Alzheimer's Foundation of America's 5 Boroughs Concepts in Care Conference. The educational conference, which takes place in New York City at the Sheraton Times Square Hotel on Friday, September 12, 2014, will bring together family caregivers, healthcare professionals and individuals with Alzheimer's disease. Experts in the field are scheduled to make presentations and attendees will receive first-hand perspectives on the medical, behavioral and practical issues faced by people with Alzheimer's disease and those around them.
Anavex to Present at Rodman & Renshaw 16th Annual Global Investment Conference
GlobeNewswire - Wed Sep 03, 6:27AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, today announced that its President and Chief Executive Officer Christopher U. Missling, PhD, will be presenting at the Rodman & Renshaw 16 Annual Global Investment Conference on Wednesday, September 10, 2014 at 1:40 p.m. ET in the Adams Salon of the New York Palace Hotel. Investors not able to attend in person may view Dr. Missling's presentation via a live webcast, which will also be archived on Anavex's website.
Anavex Selects The Alfred Hospital in Melbourne, Australia as Lead Site for Phase 2a Alzheimer's Clinical Trial
GlobeNewswire - Tue Aug 26, 6:27AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, has selected The Alfred Hospital in Melbourne, Australia as the lead site for its upcoming Phase 2a clinical trial for ANAVEX 2-73, which is being developed as a potential disease-modifying treatment for Alzheimer's disease. In total, the trial will involve up to seven experienced Alzheimer's disease clinical trial sites in Melbourne. The clinical trial, including the commencement of patient recruitment, has been submitted to The Alfred Hospital's Ethics Committee for approval.
Anavex Reports That Antidepressant Fluvoxamine Reduces Stress Through Sigma-1 Receptor
GlobeNewswire - Tue Aug 19, 7:39AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, announced today new data published in the current issue of Cell Death and Disease that the commonly used selective serotonin reuptake inhibitor (SSRI) Fluvoxamine has a high affinity for sigma-1 receptor (S1R) and thus can alleviate cell stress.
Anavex Reports Fiscal Third Quarter 2014 Financial Results
GlobeNewswire - Wed Aug 13, 6:17AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, today reported financial results for the three and nine months ended June 30, 2014.
Anavex Appoints Experienced Pharma Executive as Vice President of Clinical Operations
GlobeNewswire - Thu Aug 07, 6:48AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB: AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, announced today the appointment of Tasos Zografidis, PhD as Vice President, Clinical Operations. In this newly created position, Dr. Zografidis will be responsible for managing Anavex's clinical programs, including the upcoming Phase 2a clinical trial for ANAVEX 2-73 and ANAVEX PLUS, the Company's lead drug candidate combination in Alzheimer's disease.
Anavex Achieves Key Milestone as it Secures cGMP Manufacturing for Drug Candidate Trial Supplies
GlobeNewswire - Mon Jul 21, 6:27AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, today announced that it has secured cGMP manufacturing of ANAVEX 2-73 for its drug candidate trial supplies.
ANAVEX 3-71 Highly Effective and Disease-Modifying Against All Major Alzheimer's Hallmarks in Preclinical Disease Model
GlobeNewswire - Mon Jul 14, 6:27AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, has unveiled promising preclinical data for ANAVEX 3-71 (formerly AF710B) in a presentation at the 2014 Alzheimer's Association International Conference (AAIC).
Anavex Announces Report Expanding Opportunity for Therapeutic Application of Anavex Compounds
GlobeNewswire - Mon Jun 30, 6:27AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, today announced that a paper in the current issue of the peer-reviewed scientific journal, Neurochemical Research, reveals for the first time that sigma-1 receptors (S1R) functionally downregulate certain proteins that play a major role in various pathophysiological conditions including depression, anxiety, epilepsy and brain injury following ischemic stroke.
Anavex Strengthens Alzheimer's Pipeline, Obtains Exclusive Worldwide Rights to Intellectual Property
GlobeNewswire - Mon Mar 31, 7:15AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's, diseases of the central nervous system (CNS) and various types of cancer, announced today that it has strengthened its Alzheimer's pipeline by obtaining exclusive rights to worldwide patents and patent applications covering methods and compositions for AF710B and other related, preclinical stage compounds from Life Science Research Israel Ltd. (LSRI). LSRI has a proven track record of successfully developing and bringing drugs to market. The licensing of AF710B complements Anavex's existing pipeline in Alzheimer's disease, which is the company's core competency and includes lead clinical candidate ANAVEX PLUS.
Anavex Reports Predicted Clinical Effect of Both ANAVEX 2-73 and ANAVEX PLUS in a Humanized Cortical Cognitive Model for Alzheimer's Disease
GlobeNewswire - Thu Mar 27, 12:00PM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's, diseases of the central nervous system (CNS) and various types of cancer, today announced that a report in the current issue of peer-reviewed International Pharmaceutical Industry Journal ("IPI Journal" predicts that ANAVEX 2-73 will have a meaningful effect in Alzheimer's disease based on the Alzheimer's Disease Assessment Scale-Cognitive ("ADAS-Cog" , especially when combined with donepezil (Aricept(R)), the world's best-selling Alzheimer's drug. The Company believes this drug combination, called ANAVEX PLUS, is a compelling commercial opportunity because of its potential to treat symptoms of Alzheimer's while also possibly modifying or reversing the course of the disease. A Phase 1b/2a clinical trial of ANAVEX PLUS, is scheduled to begin mid 2014.
Anavex Successfully Closes $10 Million Financing to Initiate Phase 1b/2a Alzheimer's Clinical Trial
GlobeNewswire - Wed Mar 19, 6:37AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's, diseases of the central nervous system (CNS) and various types of cancer, announced today that it has closed, as previously announced on March 13, 2014, the private placement of $10 million in principal amount of convertible debentures with several institutional and accredited investors, including U.S. and international healthcare funds. In addition, the investors received warrants to purchase up to approximately 66.7 million shares of common stock in the aggregate.
Anavex Life Sciences signs USD10m private placement to execute clinical trial Phase 1b/2a in Alzheimer's and advance product portfolio
M2 - Fri Mar 14, 4:01AM CDT
Biopharmaceutical company Anavex Life Sciences (Other OTC:AVXL) said on Thursday that it has signed a private placement of USD10m of convertible debentures with several institutional and accredited investors, including US and international healthcare funds,.
Anavex Announces $10 Million Private Placement of Convertible Debentures
GlobeNewswire - Thu Mar 13, 9:36AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's, diseases of the central nervous system (CNS) and various types of cancer, announced today that it has entered into definitive agreements with several institutional and accredited investors, including U.S. and international healthcare funds, for a private placement of approximately $10 million in principal amount of convertible debentures. In addition, the investors will receive warrants to purchase up to approximately 66.7 million shares of common stock in the aggregate.
Anavex Encouraged By Scientific Data Confirming Sigma-1 Receptor Agonist Extends Survival in ALS (Lou Gehrig's Disease)
GlobeNewswire - Mon Mar 10, 6:39AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's, diseases of the central nervous system (CNS) and various types of cancer, today announced the findings of a research report published in the current issue of peer-reviewed scientific journal Neuroscience Letters. The Company is encouraged by the report because its results point to potential for ANAVEX 2-73 to treat ALS, also known as Lou Gehrig's disease. Data showed that sigma-1 receptor (S1R) agonists are effective in suppressing motor neuron degeneration and symptom progression in ALS animal models.
Anavex: Research Report Reveals Cardioprotective Action of Sigma-1 Receptor Agonists
GlobeNewswire - Tue Mar 04, 6:33AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL) is encouraged by the findings of a research report published in the current issue of peer-reviewed scientific journal Life Sciences. Among its conclusions, the report reveals that sigma-1 receptor (S1R) agonists play an important role in the prevention, delay or reduction of heart disease. These findings correlate with the positive electrocardiogram (EKG) parameters in the successfully completed human clinical Phase 1 safety trial of ANAVEX 2-73, an orally available S1R agonist drug candidate developed to treat Alzheimer's through potential disease modification. ANAVEX 2-73 has also shown highly encouraging synergy with donepezil, the world's best-selling Alzheimer's drug, and a Phase 1b/2a clinical trial of this combination, ANAVEX PLUS, is planned for the first half of 2014.
Research Report Confirms Opportunity for Anavex Anti-Cancer and Neuropathic Pain Compounds
GlobeNewswire - Wed Feb 26, 7:42AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL) today announced that a research article in the current issue of peer-reviewed scientific journal Molecular Pain reveals a new opportunity for the Company's anti-cancer and neuropathic pain compounds. The article describes that sigma-1 receptor (S1R) modulation prevents neuropathic pain and mitochondrial abnormalities induced by the chemotherapy drug paclitaxel.
Anavex to Present at 16th Annual BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 03, 6:27AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL) today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will be presenting at the 16th Annual BIO CEO & Investor Conference on Monday, February 10, 2014, at 1:00 p.m. ET in the Conrad Room. The conference will be held at the Waldorf-Astoria Hotel in New York, NY.
Sigma-1 receptor Implicated in Cell Survival of Rare Neurodegenerative Diseases - Expanding the Opportunity for Application of ANAVEX PLUS in Rare Diseases
GlobeNewswire - Thu Jan 23, 6:17AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL) today announced that a publication in the current issue of scientific journal Neuropathology potentially extends the opportunity for ANAVEX PLUS to additional neurodegenerative diseases beyond Alzheimer's.
Inflammatory Pain Therapeutics Pipeline Review 2014 - 36 Companies and 67 Drug Profiles
M2 - Thu Sep 11, 4:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v44nlf/inflammatory_pain) has announced the addition of the "Inflammatory Pain - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Inflammatory Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammatory Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Takeda Pharmaceutical Company Limited - Glenmark Pharmaceuticals Ltd. - Pfizer Inc. - Evotec AG - Anavex Life Sciences Corp. - Array BioPharma Inc. - Pluristem Therapeutics Inc. - BCN Peptides, S.A. - Upsher-Smith Laboratories, Inc. - Grunenthal GmbH - Integral Molecular, Inc. - AngioChem Inc. - Asahi Kasei Pharma Corp. - Hydra Biosciences, Inc. - NeurAxon, Inc. - Cara Therapeutics, Inc. - CLL Pharma - Dompe Farmaceutici S.p.A. - Lohocla Research Corporation - MAKScientific, LLC - RaQualia Pharma Inc. - Sunovion Pharmaceuticals Inc. - Adynxx, Inc. - Kareus Therapeutics, SA - AnaBios Corporation - Creabilis SA - Istituto Italiano di Tecnologia - Infirst Healthcare Limited - AbbVie Inc. - Epirus Biopharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/v4...atory_pain
Anavex Supports Alzheimer's Foundation of America's 3rd Annual Concepts in Care Educational Conference
GlobeNewswire - Mon Sep 08, 6:36AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, today announced its corporate sponsorship of the upcoming Alzheimer's Foundation of America's 5 Boroughs Concepts in Care Conference. The educational conference, which takes place in New York City at the Sheraton Times Square Hotel on Friday, September 12, 2014, will bring together family caregivers, healthcare professionals and individuals with Alzheimer's disease. Experts in the field are scheduled to make presentations and attendees will receive first-hand perspectives on the medical, behavioral and practical issues faced by people with Alzheimer's disease and those around them. Anavex to Present at Rodman & Renshaw 16th Annual Global Investment Conference
GlobeNewswire - Wed Sep 03, 6:27AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, today announced that its President and Chief Executive Officer Christopher U. Missling, PhD, will be presenting at the Rodman & Renshaw 16 Annual Global Investment Conference on Wednesday, September 10, 2014 at 1:40 p.m. ET in the Adams Salon of the New York Palace Hotel. Investors not able to attend in person may view Dr. Missling's presentation via a live webcast, which will also be archived on Anavex's website. Anavex Selects The Alfred Hospital in Melbourne, Australia as Lead Site for Phase 2a Alzheimer's Clinical Trial
GlobeNewswire - Tue Aug 26, 6:27AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, has selected The Alfred Hospital in Melbourne, Australia as the lead site for its upcoming Phase 2a clinical trial for ANAVEX 2-73, which is being developed as a potential disease-modifying treatment for Alzheimer's disease. In total, the trial will involve up to seven experienced Alzheimer's disease clinical trial sites in Melbourne. The clinical trial, including the commencement of patient recruitment, has been submitted to The Alfred Hospital's Ethics Committee for approval. Anavex Reports That Antidepressant Fluvoxamine Reduces Stress Through Sigma-1 Receptor
GlobeNewswire - Tue Aug 19, 7:39AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, announced today new data published in the current issue of Cell Death and Disease that the commonly used selective serotonin reuptake inhibitor (SSRI) Fluvoxamine has a high affinity for sigma-1 receptor (S1R) and thus can alleviate cell stress. Anavex Reports Fiscal Third Quarter 2014 Financial Results
GlobeNewswire - Wed Aug 13, 6:17AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, today reported financial results for the three and nine months ended June 30, 2014. Anavex Appoints Experienced Pharma Executive as Vice President of Clinical Operations
GlobeNewswire - Thu Aug 07, 6:48AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQB: AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, announced today the appointment of Tasos Zografidis, PhD as Vice President, Clinical Operations. In this newly created position, Dr. Zografidis will be responsible for managing Anavex's clinical programs, including the upcoming Phase 2a clinical trial for ANAVEX 2-73 and ANAVEX PLUS, the Company's lead drug candidate combination in Alzheimer's disease. Anavex Achieves Key Milestone as it Secures cGMP Manufacturing for Drug Candidate Trial Supplies
GlobeNewswire - Mon Jul 21, 6:27AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, today announced that it has secured cGMP manufacturing of ANAVEX 2-73 for its drug candidate trial supplies. ANAVEX 3-71 Highly Effective and Disease-Modifying Against All Major Alzheimer's Hallmarks in Preclinical Disease Model
GlobeNewswire - Mon Jul 14, 6:27AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, has unveiled promising preclinical data for ANAVEX 3-71 (formerly AF710B) in a presentation at the 2014 Alzheimer's Association International Conference (AAIC). Anavex Announces Report Expanding Opportunity for Therapeutic Application of Anavex Compounds
GlobeNewswire - Mon Jun 30, 6:27AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, today announced that a paper in the current issue of the peer-reviewed scientific journal, Neurochemical Research, reveals for the first time that sigma-1 receptors (S1R) functionally downregulate certain proteins that play a major role in various pathophysiological conditions including depression, anxiety, epilepsy and brain injury following ischemic stroke. Anavex Strengthens Alzheimer's Pipeline, Obtains Exclusive Worldwide Rights to Intellectual Property
GlobeNewswire - Mon Mar 31, 7:15AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQB:AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's, diseases of the central nervous system (CNS) and various types of cancer, announced today that it has strengthened its Alzheimer's pipeline by obtaining exclusive rights to worldwide patents and patent applications covering methods and compositions for AF710B and other related, preclinical stage compounds from Life Science Research Israel Ltd. (LSRI). LSRI has a proven track record of successfully developing and bringing drugs to market. The licensing of AF710B complements Anavex's existing pipeline in Alzheimer's disease, which is the company's core competency and includes lead clinical candidate ANAVEX PLUS. Anavex Reports Predicted Clinical Effect of Both ANAVEX 2-73 and ANAVEX PLUS in a Humanized Cortical Cognitive Model for Alzheimer's Disease
GlobeNewswire - Thu Mar 27, 12:00PM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQB:AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's, diseases of the central nervous system (CNS) and various types of cancer, today announced that a report in the current issue of peer-reviewed International Pharmaceutical Industry Journal ("IPI Journal" predicts that ANAVEX 2-73 will have a meaningful effect in Alzheimer's disease based on the Alzheimer's Disease Assessment Scale-Cognitive ("ADAS-Cog" , especially when combined with donepezil (Aricept(R)), the world's best-selling Alzheimer's drug. The Company believes this drug combination, called ANAVEX PLUS, is a compelling commercial opportunity because of its potential to treat symptoms of Alzheimer's while also possibly modifying or reversing the course of the disease. A Phase 1b/2a clinical trial of ANAVEX PLUS, is scheduled to begin mid 2014. Anavex Successfully Closes $10 Million Financing to Initiate Phase 1b/2a Alzheimer's Clinical Trial
GlobeNewswire - Wed Mar 19, 6:37AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQB:AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's, diseases of the central nervous system (CNS) and various types of cancer, announced today that it has closed, as previously announced on March 13, 2014, the private placement of $10 million in principal amount of convertible debentures with several institutional and accredited investors, including U.S. and international healthcare funds. In addition, the investors received warrants to purchase up to approximately 66.7 million shares of common stock in the aggregate. Anavex Life Sciences signs USD10m private placement to execute clinical trial Phase 1b/2a in Alzheimer's and advance product portfolio
M2 - Fri Mar 14, 4:01AM CDT
Biopharmaceutical company Anavex Life Sciences (Other OTC:AVXL) said on Thursday that it has signed a private placement of USD10m of convertible debentures with several institutional and accredited investors, including US and international healthcare funds,.
Anavex Announces $10 Million Private Placement of Convertible Debentures
GlobeNewswire - Thu Mar 13, 9:36AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQB:AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's, diseases of the central nervous system (CNS) and various types of cancer, announced today that it has entered into definitive agreements with several institutional and accredited investors, including U.S. and international healthcare funds, for a private placement of approximately $10 million in principal amount of convertible debentures. In addition, the investors will receive warrants to purchase up to approximately 66.7 million shares of common stock in the aggregate. Anavex Encouraged By Scientific Data Confirming Sigma-1 Receptor Agonist Extends Survival in ALS (Lou Gehrig's Disease)
GlobeNewswire - Mon Mar 10, 6:39AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQB:AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's, diseases of the central nervous system (CNS) and various types of cancer, today announced the findings of a research report published in the current issue of peer-reviewed scientific journal Neuroscience Letters. The Company is encouraged by the report because its results point to potential for ANAVEX 2-73 to treat ALS, also known as Lou Gehrig's disease. Data showed that sigma-1 receptor (S1R) agonists are effective in suppressing motor neuron degeneration and symptom progression in ALS animal models. Anavex: Research Report Reveals Cardioprotective Action of Sigma-1 Receptor Agonists
GlobeNewswire - Tue Mar 04, 6:33AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQB:AVXL) is encouraged by the findings of a research report published in the current issue of peer-reviewed scientific journal Life Sciences. Among its conclusions, the report reveals that sigma-1 receptor (S1R) agonists play an important role in the prevention, delay or reduction of heart disease. These findings correlate with the positive electrocardiogram (EKG) parameters in the successfully completed human clinical Phase 1 safety trial of ANAVEX 2-73, an orally available S1R agonist drug candidate developed to treat Alzheimer's through potential disease modification. ANAVEX 2-73 has also shown highly encouraging synergy with donepezil, the world's best-selling Alzheimer's drug, and a Phase 1b/2a clinical trial of this combination, ANAVEX PLUS, is planned for the first half of 2014. Research Report Confirms Opportunity for Anavex Anti-Cancer and Neuropathic Pain Compounds
GlobeNewswire - Wed Feb 26, 7:42AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQB:AVXL) today announced that a research article in the current issue of peer-reviewed scientific journal Molecular Pain reveals a new opportunity for the Company's anti-cancer and neuropathic pain compounds. The article describes that sigma-1 receptor (S1R) modulation prevents neuropathic pain and mitochondrial abnormalities induced by the chemotherapy drug paclitaxel. Anavex to Present at 16th Annual BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 03, 6:27AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQB:AVXL) today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will be presenting at the 16th Annual BIO CEO & Investor Conference on Monday, February 10, 2014, at 1:00 p.m. ET in the Conrad Room. The conference will be held at the Waldorf-Astoria Hotel in New York, NY. Sigma-1 receptor Implicated in Cell Survival of Rare Neurodegenerative Diseases - Expanding the Opportunity for Application of ANAVEX PLUS in Rare Diseases
GlobeNewswire - Thu Jan 23, 6:17AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQB:AVXL) today announced that a publication in the current issue of scientific journal Neuropathology potentially extends the opportunity for ANAVEX PLUS to additional neurodegenerative diseases beyond Alzheimer's. 
